Quest Diagnostics, a leader in medical testing, has experienced a series of notable events as per recent reports. The company elected Robert B. Carter, CIO of FedEx Corporation, to its board of directors, demonstrating a likely shift towards greater digital innovation and logistics efficiency. Moreover, Quest's base volume seems to be reviving and a new regulatory ruling is playing to its advantage.
Zacks Research reports an earnings forecast of $2.26 per share for Q2 2024, a positive indication for future investor returns. The company also raised its guidance for the full year 2024 after releasing the first quarter financial report.
Quest Diagnostics has been making significant advancements in digital pathology with a new deal, which is expected to accelerate AI and digital pathology adoption in cancer diagnosis. It appears the company is close to acquiring Canada's LifeLabs, a move that will likely broaden its market reach.
A series of buyouts, collaborations, and service upgrades have been outlined for Quest Diagnostics as well, including a lab service deal with ReproSource and a strategic collaboration with Universal DX. Whether these efforts will achieve tangible results remains to be seen.
Quest Diagnostics DGX News Analytics from Tue, 11 Jul 2023 07:00:00 GMT to Thu, 16 May 2024 21:19:28 GMT - Rating 7 - Innovation 9 - Rumor -2
